盐酸埃克替尼在晚期非小细胞肺癌治疗中的应用研究  

Application Study on Icotinib Hydrochloride in Treating Patients with Advanced Non-Small Cell Lung Cancer

作　　者：任柏沉[1] 李燕宏[1] 孙健[1] 李云辉[1] 

机构地区：[1]成都医学院第一附属医院呼吸内科,成都610500

出　　处：《成都医学院学报》2015年第5期591-594,共4页Journal of Chengdu Medical College

摘　　要：目的探讨盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）的临床疗效。方法选取2010年7月至2012年6月成都医学院第一附属医院收治的晚期NSCLC患者88例作为研究对象,按照随机数字表法1∶1,分为试验组与对照组,每组各44例。试验组以盐酸埃克替尼治疗,对照组以多西他赛或培美曲塞二钠治疗,观察两组临床疗效及不良反应。结果两组客观缓解率、6个月控制率和中位无进展生存时间（PFS）比较,差异无统计学意义（P〉0.05）;两组EGFR基因突变患者部分缓解（PR）、未突变和未知患者PR比较,差异无统计学意义（P〉0.05）;两组Ⅰ~Ⅱ度不良反应发生率比较,差异无统计学意义（P〉0.05）;试验组Ⅲ度不良反应发生率与对照组比较,差异有统计学意义（P〈0.05）。结论在晚期NSCLC治疗上,盐酸埃克替尼与传统二线化疗药物具有相似疗效,且Ⅲ度不良反应发生率低。Objective To study the clinical effects of icotinib hydrochloride in treating patients with advanced non-small cell lung cancer（NSCLC）.Methods 88 patients with advanced NSCLC treated in our hospital from July2010 to June 2012 were selected and were divided into experimental group（n=44）and control group（n=44）based on a 1∶1ratio using random number table method.The experimental group was treated with icotinib hydrochloride,while the control group was treated with docetaxel or pemetrexed disodium.Clinical effects and adverse reactions of the two groups were observed.Results No statistically significant difference was found in terms of objective remission rate,half year control rate,median progression-free survival time（PFS）and the average PFS between the experimental group and the control group（P〉0.05）.Meanwhile,no statistically significant difference was found in terms of partial remission rate（PR）of patients with EGFR gene mutation,PR rate of patients without mutations and PR rate of patients with unknown state between the two groups（P〉0.05）.The incidence rate of adverse reactions of degreeⅠ orⅡin experimental group has no statistically significant difference with that of control group（P〉0.05）,while there was statistically significant difference in the incidence rate of adverse reactions of degreeⅢbetween the two groups（P〈0.05）.Conclusion In the treatment of advanced NSCLC,the efficacy of icotinib hydrochloride is closer to that of traditional second-line chemotherapeutics,and the incidence rate of adverse reactions of degreeⅢ has been low.

关 键 词：盐酸埃克替尼 晚期NSCLC 疗效 不良反应 

分 类 号：R730.5[医药卫生—肿瘤] R979.1[医药卫生—临床医学]